Relmada Therapeutics (STU:4E2) Accounts Payable & Accrued Expense : €3.90 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Relmada Therapeutics Accounts Payable & Accrued Expense?

Relmada Therapeutics's quarterly accounts payable & accrued expense increased from Sep. 2024 (€6.06 Mil) to Dec. 2024 (€8.73 Mil) but then declined from Dec. 2024 (€8.73 Mil) to Mar. 2025 (€3.90 Mil).

Relmada Therapeutics's annual accounts payable & accrued expense declined from Dec. 2022 (€10.81 Mil) to Dec. 2023 (€8.43 Mil) but then increased from Dec. 2023 (€8.43 Mil) to Dec. 2024 (€8.73 Mil).

Relmada Therapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for Relmada Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relmada Therapeutics Accounts Payable & Accrued Expense Chart

Relmada Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

8.88

11.88

10.81

8.43

8.73

Relmada Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															10.75	7.92	6.06	8.73	3.90

Relmada Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Relmada Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (STU:4E2) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

RLMD:USA

Address

2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134

Website

https://www.relmada.com

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Relmada Therapeutics Headlines

No Headlines